Synopsis The second-line antidiabetic medications (ADMs) are associated with cardiovascular events among insured patients with type 2 diabetes who are initiating second-line therapy. The present study highlights the newer ADM classes to be followed more routinely after metformin rather than sulfonylureas or basal insulin. This week’s “ MED FACT ” discusses a clinical trial from Jama Network Open, “Association of Second-line ADM Classes with Major Adverse Cardiovascular Events”. Author s :   MatthewJ. O’Brien, Susan L. Karam, Amisha Wallia, Raymond H. Kang, Andrew J.

Cooper, Nicola Lancki, Margaret R. Moran, David T. Liss, Theodore A. Prospect, Ronald T. Ackermann . Key Takeaways: Important insight into the association of higher cardiovascular risk with use of sulfonylureas or basal insulin compared with newer ADM classes. Doctors may consider prescribing GLP-1 receptor agonists, SGLT-2…